title: Contemporary outcomes after endovascular treatment for aorto-iliac artery disease.
abstract: BACKGROUND
  The patency and complications in aorto-iliac (AI) stenting remain poorly understood. The aim of this paper was to investigate the safety and efficacy after AI stenting.
  
  
  RESULTS
  This study was performed as a large-scale multicenter, retrospective registry. A total of 2,147 consecutive patients with AI disease were enrolled. The safety endpoints were procedure success, complications and 30-day mortality. The efficacy endpoints were primary, assisted primary and secondary patency, overall survival, freedom from major adverse cardiovascular events (MACE; all-cause death, myocardial infarction and stroke), and major adverse cardiovascular and limb events (MACLE; any repeat revascularization for limb and leg amputation in addition to MACE). Procedure success, complication rate and 30-day mortality were 97.6%, 6.4% and 0.7%. Primary patency was 92.5%, 82.6% and 77.5% at 1, 3 and 5 years, assisted primary patency was 97.0%, 92.7% and 91.9% at 1, 3 and 5 years and secondary patency was 99.0%, 98.7% and 98.5% at 1, 3 and 5 years. The overall survival rate was 95.0%, 87.6%, and 79.3% at 1, 3 and 5 years. The cause of death was cardiovascular in 44.1%. Freedom from MACE (MACLE) was 93.3% (89.9%), 84.4% (76.7%), and 74.9% (66.8%) at 1, 3 and 5 years. Female gender, diabetes, renal failure, absence of aspirin, reference vessel diameter <8.0mm and outflow lesion were found to be independent predictors of primary patency.
  
  
  CONCLUSIONS
  The safety and efficacy after AI stenting are feasible compared to surgical reconstruction.
authors.affiliation: Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan. sogacchy@yahoo.co.jp
authors.forename: Yoshimitsu
authors.initials: Y
authors.lastname: Soga
authors.forename: Osamu
authors.initials: O
authors.lastname: Iida
authors.forename: Daizo
authors.initials: D
authors.lastname: Kawasaki
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Yamauchi
authors.forename: Kenji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Keisuke
authors.initials: K
authors.lastname: Hirano
authors.forename: Ryoji
authors.initials: R
authors.lastname: Koshida
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kamoi
authors.forename: Junichi
authors.initials: J
authors.lastname: Tazaki
authors.forename: Michiaki
authors.initials: M
authors.lastname: Higashitani
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Shintani
authors.forename: Terutoshi
authors.initials: T
authors.lastname: Yamaoka
authors.forename: Shinya
authors.initials: S
authors.lastname: Okazaki
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Suematsu
authors.forename: Taketsugu
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Miyashita
authors.forename: Norihiko
authors.initials: N
authors.lastname: Shinozaki
authors.forename: Hiroki
authors.initials: H
authors.lastname: Takahashi
mesh_terms: D000368:Aged; D001018:Aortic Diseases / Q000401:mortality* / Q000503:physiopathology* / Q000601:surgery; D019917:Blood Vessel Prosthesis Implantation; D018572:Disease-Free Survival; D057510:Endovascular Procedures; D005260:Female; D006801:Humans; D007083:Iliac Artery; D008297:Male; D008875:Middle Aged; D012042:Registries; D012189:Retrospective Studies; D012737:Sex Factors; D015607:Stents; D015996:Survival Rate; D013997:Time Factors; D014654:Vascular Patency